Clearside Biomedical's Leadership in Suprachoroidal Delivery Featured in Multiple Presentations at the Clinical Trials at the Summit Meeting
Clearside Biomedical(CLSD) GlobeNewswire News Room·2024-06-12 19:05- Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications - - Robust Safety Profile and Encouraging Efficacy Data Reported Utilizing SCS Microinjector® - ALPHARETTA, Ga., June 12, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that multiple oral presentations were delivered at the Clinical Trials at the Summit ...